Phibro Animal Health (PAHC) Draws Fresh Valuation Attention, Is It Still Below Fair Value?
Phibro Animal Health (PAHC) has drawn fresh attention after recent trading, with the share price at $37.40 as of 7 October 2026. Investors are reassessing its long term performance and current valuation.
Recent trading has been choppy for Phibro Animal Health, with the share price down 0.85% on the day but still showing a 16.62% 90 day share price return and a very large 3 year total shareholder return, which suggests that momentum has been rebuilding after earlier gains.
Scan how Phibro Animal Health compares with other businesses showing fresh momentum and resilient fundamentals inside our curated 27 high quality undervalued stocks.
Bulls point to Phibro Animal Health’s strong multi year shareholder returns and ongoing revenue and net income growth. Bears focus on recent volatility and debate whether the valuation already reflects that progress. Which case do the numbers support next?
Most Popular Narrative: 15% Undervalued
On the widely followed narrative, Phibro Animal Health screens as undervalued, with an indicated fair value of $44 against the recent $37.40 close. This puts the spotlight on whether execution can close that gap.
The current valuation implies the share price does not fully reflect the record fiscal 2026 results, expected EBITDA contributions from efficiency programs and manufacturing changes, or the potential of newer sustainability related offerings.
See why 8 investors see Phibro Animal Health as 15% undervalued.
Result: Fair Value of $44 (UNDERVALUED)
Still, the Phibro Animal Health story can change quickly if higher capex fails to lift margins or if regulatory shifts pressure high margin antimicrobial revenue.
Find out about the key risks to this Phibro Animal Health narrative.
Another View: Phibro Animal Health Through Market Multiples
A different lens on Phibro Animal Health comes from its P/E ratios. The stock trades on 15.4x earnings, which is higher than both peers at 11.6x and the wider US Pharmaceuticals group at 15.1x. Yet the fair ratio sits at 17.4x, suggesting the market could shift closer to that level over time. For investors, that mix of slight sector premium and discount to the fair ratio points to valuation risk if sentiment cools, but also some potential upside if earnings delivery matches expectations. Which outcome feels more realistic to you at today’s price?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages in the Phibro Animal Health story today. Act while the data is fresh and pressure test both sides by reviewing the 3 key rewards and 1 important warning sign.
Looking for more Phibro Animal Health sized ideas?
If Phibro Animal Health has sharpened your thinking, keep building your shortlist with fresh ideas that match your risk profile, income needs, and quality filter.
- Hunt for resilient businesses that prioritise balance sheet strength inside our list of solid balance sheet and fundamentals (25 results).
- Target income potential by scanning companies that feature in our 8 dividend fortresses.
- Unearth future candidates for your watchlist by reviewing the 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com